Healthy
Conditions
Brief summary
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in healthy individuals - during baseline conditions and after activation of the sympathetic nervous system.
Interventions
DRUGEprosartan
Sponsors
Regional Hospital Holstebro
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Both genders. * Age 18 - 65 years. * Body mass index less or equal to 30 kg/m2. * Women must use oral hormonal anticonception, use intrauterine anticonceptive device, be sterilized/hysterectomized or be postmenopausal.
Exclusion criteria
* History or clinical signs of heart, lung, kidney, or endocrine organ disease. * Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase, P-alkaline phosphatase, P-cholesterol, and B-glucose. * Abnormal screening of the urine regarding: albumin and glucose * Malignant disease. * Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic. * Alcohol abuse. * Smoking. * Drug use or abuse. * Known intolerance or allergy to eprosartan or sodium nitroprusside. * Blood donation within 1 month of the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart rate | — |
| Fractional sodium excretion | — |
| Plasma levels of noradrenaline | — |
Countries
Denmark
Outcome results
None listed